专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140357870A1 PROCESS FOR THE PREPARATION OF DEXLANSOPRAZOLE 审中-公开
标题翻译：二氯吡唑的制备方法
公开(公告)号：US20140357870A1
公开(公告)日：2014-12-04
申请号：US14127680
申请日：2012-06-20
申请人： Anmol Kumar Ray , Anu Mittal , Nagaraju Gottumukkala , Mahavir Singh Khanna , Rajesh Kumar Thaper , Mohan Prasad , Sudershan Kumar Arora
发明人： Anmol Kumar Ray , Anu Mittal , Nagaraju Gottumukkala , Mahavir Singh Khanna , Rajesh Kumar Thaper , Mohan Prasad , Sudershan Kumar Arora
IPC分类号： C07D401/12
CPC分类号： C07D401/12
摘要： The present invention relates to a process for the preparation of dexlansoprazole.xH2O, wherein x is about 0.0 to about 0.1, using dexlansoprazole.xH2O, wherein x is about 2.6 to about 50.
摘要翻译：本发明涉及使用右兰索拉唑×H 2 O制备右兰索拉唑×H 2 O的方法，其中x为约0.0至约0.1，其中x为约2.6至约50。

2. 发明申请

US20140343290A1 PROCESS FOR THE PREPARATION OF ATAZANAVIR OR ITS BISULFATE SALT 审中-公开
标题翻译：制备ATAZANAVIR或其BISULFATE盐的方法
公开(公告)号：US20140343290A1
公开(公告)日：2014-11-20
申请号：US14235127
申请日：2012-07-25
申请人： Rakesh Kumar Singh , Nagaraju Gottumukkala , Mahavir Singh Khanna , Rajesh Kumar Thaper , Mohan Prasad , Sudershan Kumar Arora
发明人： Rakesh Kumar Singh , Nagaraju Gottumukkala , Mahavir Singh Khanna , Rajesh Kumar Thaper , Mohan Prasad , Sudershan Kumar Arora
IPC分类号： C07D213/42
CPC分类号： C07D213/42
摘要： The present invention relates to an improved process for the preparation of atazanavir bisulfate, an inhibitor of retroviral aspartate protease. The process of the present invention comprises conversion of 1,1-dimethylethyl[(2S,3R)-4-chloro-3-hydroxy-phenylbutan-2-yl]carbamate (Formula II) into 1-[4-(pyridine-2-yl)-phenyl]-4(S)-5 hydroxy-2-N-tert-butoxycarbonylamino-5(S)—N—(N-methoxycarbonyl-(L)-tert-leucyl)amino-6-phenyl-2-azahexane (Formula VII) without isolating intermediate compounds formed therein, followed by its subsequent conversion to atazanavir or its bisulfate salt.
摘要翻译：本发明涉及一种制备逆转录病毒天冬氨酸蛋白酶抑制剂阿扎那韦硫酸氢盐的改进方法。本发明的方法包括将[（2S，3R）-4-氯-3-羟基 - 苯基丁-2-基]氨基甲酸酯（式II）的1,1-二甲基乙基酯转化为1- [4-（吡啶-2 - 基） - 苯基] -4（S）-5-羟基-2-N-叔丁氧基羰基氨基-5（S）-N-（N-甲氧基羰基 - （L） - 叔 - 亮氨酰基）氨基-6-苯基-2 （式Ⅶ），而不分离其中形成的中间体化合物，随后转化成阿扎那韦或其硫酸氢盐。

3. 发明申请

US20150025080A1 SOLID DISPERSIONS OF SITAGLIPTIN AND PROCESSES FOR THEIR PREPARATION 审中-公开
标题翻译： SITAGLIPTIN的固体分散体及其制备方法
公开(公告)号：US20150025080A1
公开(公告)日：2015-01-22
申请号：US14129687
申请日：2012-06-29
申请人： Poonam Kaushik , Ram Thaimattam , Mohan Prasad , Sudershan Kumar Arora
发明人： Poonam Kaushik , Ram Thaimattam , Mohan Prasad , Sudershan Kumar Arora
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： The present invention provides processes for the preparation of amorphous form of sitagliptin dihydrogen phosphate. It also provides a solid dispersion of sitagliptin dihydrogen phosphate, including in the amorphous form, and processes for its preparation.
摘要翻译：本发明提供了制备西格列汀磷酸二氢盐的无定形形式的方法。它还提供了西他列汀磷酸二氢钠的固体分散体，包括无定形形式，及其制备方法。

4. 发明授权

US07601368B2 Purified Arabinogalactan-Protein (AGP) composition useful in the treatment psoriasis and other disorders 失效
标题翻译：纯化的阿拉伯半乳聚糖蛋白（AGP）组合物可用于治疗牛皮癣和其他疾病
公开(公告)号：US07601368B2
公开(公告)日：2009-10-13
申请号：US10931814
申请日：2004-09-01
申请人： Sudershan Kumar Arora , Vandita Srivastava , Sameer Shankar Walunj
发明人： Sudershan Kumar Arora , Vandita Srivastava , Sameer Shankar Walunj
IPC分类号： A61K36/00
CPC分类号： A61K36/66 , Y02A50/39
摘要： A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-γ inhibition, or IL-10 induction; keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).
摘要翻译：描述了通过选择性方法从Argemone mexicana植物的叶和/或茎分离的纯化的阿拉伯半乳聚糖蛋白（AGP）组合物。还描述了从茄科植物的叶子和/或茎分离的纯化的阿拉伯半乳聚糖蛋白（AGP）组合物，其具有以下一种或多种作用：免疫抑制，淋巴增殖抑制，细胞因子调节如IL-2抑制，IFN γ抑制或IL-10诱导; 角质形成细胞增殖抑制，角质溶解活性和小鼠耳肿胀试验（MEST）中的抑制活性。

5. 发明申请

US20090264341A1 PURIFIED ARABINOGALACTAN-PROTEIN (AGP) COMPOSITION USEFUL IN THE TREATMENT PSORIASIS AND OTHER DISORDERS 审中-公开
公开(公告)号：US20090264341A1
公开(公告)日：2009-10-22
申请号：US12496924
申请日：2009-07-02
申请人： Sudershan Kumar Arora , Vandita Srivastava , Sameer Shankar Walunj
发明人： Sudershan Kumar Arora , Vandita Srivastava , Sameer Shankar Walunj
IPC分类号： A61K38/16 , C07K2/00
CPC分类号： A61K36/66 , Y02A50/39
摘要： A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-γ inhibition, or IL-10 induction; keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).

6. 发明授权

US07491721B2 Antimycobacterial pharmaceutical composition 失效
标题翻译：抗分枝杆菌药物组合物
公开(公告)号：US07491721B2
公开(公告)日：2009-02-17
申请号：US10844992
申请日：2004-05-12
申请人： Sudershan Kumar Arora , Neelima Sinha , Rakesh Sinha , Ram Shankar Upadhyaya
发明人： Sudershan Kumar Arora , Neelima Sinha , Rakesh Sinha , Ram Shankar Upadhyaya
IPC分类号： A61K31/12 , A61K31/33 , A61K31/135 , A61K31/165 , A61K31/166
CPC分类号： A61K31/131 , A61K31/4409 , A61K31/496 , A61K31/4965 , A61K45/06 , A61K2300/00
摘要： An antimycobacterial combination and composition for treating tuberculosis are described. The compounds used are N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide of formula (I) or a pharmaceutically acceptable non-toxic salt thereof and an amount of one or more first line antitubercular drugs.
摘要翻译：描述了用于治疗结核病的抗分支杆菌组合物和组合物。使用的化合物是式（I）的N-（3 - [[4-（3-三氟甲基苯基）哌嗪基]甲基] -2-甲基-5-苯基 - 吡咯基）-4-吡啶基甲酰胺或药学上可接受的无毒盐和一种或多种一线抗结核药物。

7. 发明授权

US07232835B2 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists 失效
标题翻译： 3,6-二取代的氮杂双环衍生物作为毒蕈碱受体拮抗剂
公开(公告)号：US07232835B2
公开(公告)日：2007-06-19
申请号：US10537851
申请日：2002-12-10
申请人： Anita Mehta , Arundutt Viswanatham Silamkoti , Bruhaspathy Miriyala , Sudershan Kumar Arora , Boju Srinivasulu , Bireshwar Mukherjee , Jang Bahadur Gupta
发明人： Anita Mehta , Arundutt Viswanatham Silamkoti , Bruhaspathy Miriyala , Sudershan Kumar Arora , Boju Srinivasulu , Bireshwar Mukherjee , Jang Bahadur Gupta
IPC分类号： A01N43/40 , A01N43/00 , A61K31/445 , A61K31/55 , C07D221/02
CPC分类号： C07D401/06 , C07D209/52 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/14
摘要： This invention relates to derivatives of 3,6-disubstituted azabicyclo compounds. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
摘要翻译：本发明涉及3,6-二取代的氮杂二环化合物的衍生物。本发明化合物可用作毒蕈碱受体拮抗剂，可用于治疗通过毒蕈碱受体介导的呼吸道，尿路和胃肠道系统的各种疾病。本发明还涉及含有本发明化合物的药物组合物和通过毒蕈碱受体介导的疾病的治疗方法。

8. 发明申请

US20140350252A1 PROCESS FOR THE PREPARATION OF VORICONAZOLE AND INTERMEDIATES THEREOF 审中-公开
标题翻译：制备吡唑并唑及其中间体的方法
公开(公告)号：US20140350252A1
公开(公告)日：2014-11-27
申请号：US13985157
申请日：2012-02-21
申请人： Nitin Maheshwari , Roshan Ramesh Medhane , Mohan Prasd , Sudershan Kumar Arora
发明人： Nitin Maheshwari , Roshan Ramesh Medhane , Mohan Prasd , Sudershan Kumar Arora
IPC分类号： C07D403/06
CPC分类号： C07D403/06
摘要： The present invention relates to an improved stereoselective process for the preparation of (2R,3S/2S,3R)-3-(4-chloro-5-fluoropyrimidin-6-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol intermediate compound. This intermediate compound is further used to prepare voriconazole—a triazole antifungal agent.
摘要翻译：本发明涉及用于制备（2R，3S / 2S，3R）-3-（4-氯-5-氟嘧啶-6-基）-2-（2,4-二氟苯基）-1 - （1H-1,2,4-三唑-1-基）丁-2-醇中间体化合物。该中间体化合物进一步用于制备伏立康唑 - 三唑抗真菌剂。

9. 发明申请

US20090247545A1 SUBSTITUTED OXAZOLIDINONE DERIVATIVES 审中-公开
标题翻译：取代的氧杂环丁酮衍生物
公开(公告)号：US20090247545A1
公开(公告)日：2009-10-01
申请号：US11577083
申请日：2004-12-28
申请人： Mukund Keshao Gurjar , Madhusudan Nagorao Deshmukh , Anita Mehta , Sudershan Kumar Arora , Ashok Rattan
发明人： Mukund Keshao Gurjar , Madhusudan Nagorao Deshmukh , Anita Mehta , Sudershan Kumar Arora , Ashok Rattan
IPC分类号： A61K31/496 , C07D413/10 , A61P31/04
CPC分类号： C07D263/20 , C07D413/10
摘要： The present invention provides substituted oxazolidinone derivatives, which can be used as antimicrobial agents. Compounds disclosed can be used for the treatment or prevention of a condition caused by or contributed to by bacteria, such as, inter alia, multiply-resistant Staphylococci, Streptococci, Enterococci, Bacterioides spp., Clostridium spp., Mycobacterium spp. Bacillus spp., Corynebacterium spp. Heptoslreptacoccus spp. Listeria spp., Legionella spp., Haemophilus influenza, Moraxella, Eschericia faecalis, and Eschericia coli. Processes for the preparation of disclosed compounds, pharmaceutical compositions thereof, and method of treating microbial infection are provided.
摘要翻译：本发明提供了可用作抗微生物剂的取代的恶唑烷酮衍生物。所公开的化合物可用于治疗或预防由细菌引起的或由细菌引起的病症，例如多重耐药葡萄球菌，链球菌，肠球菌，细菌属，梭菌属，分枝杆菌属。芽孢杆菌属，棒状杆菌属肝细胞线粒体利斯特氏菌属（Listeria spp。），军团菌属（Legionella spp。），嗜血杆菌流感，流感嗜血杆菌，大肠埃希氏菌和大肠埃希氏菌。提供了制备所公开化合物的方法，其药物组合物，以及治疗微生物感染的方法。

10. 发明申请

US20090118509A1 PREPARATION OF [2-METHYL-5-PHENYL-3-(PIPERAZIN-1-YLMETHYL)] PYRROLE DERIVATIVES 审中-公开
公开(公告)号：US20090118509A1
公开(公告)日：2009-05-07
申请号：US11911272
申请日：2006-04-05
申请人： Sudershan Kumar Arora , Neelima Sinha , Sanjay Jain , Ram Shankar Upadhayaya , Om Dutt Tyagi , Vasanth Nalam , Yogendra Kumar Chauhan
发明人： Sudershan Kumar Arora , Neelima Sinha , Sanjay Jain , Ram Shankar Upadhayaya , Om Dutt Tyagi , Vasanth Nalam , Yogendra Kumar Chauhan
IPC分类号： C07D401/14
CPC分类号： C07D207/50 , C07D207/335 , C07D401/04 , C07D401/12
摘要： A process for the preparation of compounds of Formula I and their pharmaceutically acceptable acid addition salt wherein, R1 is phenyl or substituted phenyl R2 is selected from a group consisting of phenyl which is unsubstituted or substituted with 1 or 2 substituents, each independently selected from Cl, F, or pyridine, or naphthalene, or NHCOR4 wherein R4 is aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heterocyclyl. R3 is selected from a group of formula wherein R5 is phenyl which is unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 alkoxy, nitro, amino, haloalkyl, haloalkoxy etc.; unsubstituted or substituted benzyl; unsubstituted or substituted heteroaryl; unsubstituted or substituted heteroaroyl; unsubstituted or substituted diphenylmethyl, n=0-2 and X═—NCH3, CH2, S, SO, or SO2 Such that when R2 is phenyl, which is unsubstituted or substituted with 1 or 2 substituents, each independently selected from Cl, F; R5 is not C1-C4 alkyl, or X is not —NCH3, CH2, S, SO, or SO2, when n=1, or X is not —CH2 when n=0; comprising the steps of (a) reacting compound of Formula II with a chlorinating agent in the presence or absence of catalytic amount of N,N-dimethylformamide to yield the compound of Formula III, (b) reacting the compound of Formula III with a compound of Formula R1H (R1 is as defined above), in presence of a Lewis acid to obtain the compound of Formula IV, (c) reacting the compound of Formula IV with a compound of Formula R2NH2 (R2 is as defined above) in presence of catalytic amounts of an aryl or alkyl sulphonic acid in an organic solvent to obtain the compound of Formula V, (d) reacting the compound of Formula V with various secondary amines of the Formula R3H (R3 is as defined above) in the presence of formaldehyde and acetic acid in acetonitrile followed by crystallization yield the compound of Formula I, (e) purifying the compound of Formula I by crystallization, (f) converting the purified compound of Formula I to a pharmaceutically acceptable acid addition salt.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式